Early appearance of neutralizing antibodies after vaccination with an inactivated hepatitis A vaccine

Journal of Infection

Volumn 35, Issue 1, 1997, Pages 37-40

  Flehmig, B ^a   Staedele, H ^a   Xueref, C ^b   Vidor, E ^b   Zuckerman, J ^c   Zuckerman, A ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Pasteur Merieux Serums and Vaccins   (France)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG COMPARISON; DRUG EFFICACY; FEMALE; HEPATITIS A; HUMAN; IMMUNOSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; MALE; NORMAL HUMAN; RADIOIMMUNOASSAY; REVACCINATION; SERODIAGNOSIS; SEROLOGY; VACCINATION; VIRUS NEUTRALIZATION;

EID: 0030852311     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(97)90929-4     Document Type: Article

References (17)

1. Lemon SM. Hepatitis A virus: current concepts of the molecular virology, immunobiology, and approaches to vaccine development. Rev Med Virol 1992; 2: 73-87.
2. Stapleton JT, Jansen RW, Lemon SM. Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. Gastroenterology 1985; 89: 637-642.
3. Lerman Y, Shohat T, Ashkenazi S, Almog R, Heering SL, Shemer J. Efficacy of different doses of immune serum globulin in the prevention of hepatitis A: a three-year prospective study. Cli Infect Dis 1993; 17: 411-414.
4. Lemon SM, Bin LN. Serum neutralizing antibody response to hepatitis A virus. J Infect Dis 1983; 148: 1033-1039.
5. Krah DL, Amin RD, Nalin DR, Provost PJ. a simple antigen-reduction assay for the measurement of neutralizing antibodies to hepatitis A virus. J Infect Dis 1991; 163: 634-637.
6. Flehmig B. Zahn J, Vallbracht A. Levels of neutralizing and binding antibodies to Hepatitis A virus after onset of icterus: a comparison. J Infect Dis 1984; 150: 461.
7. Lemon SM, Jansen RW, Brown EA. Genetic, antigenic and biological differences between strains of hepatitis A virus. Vaccine 1992; 10: S40-S44.
8. Ellerbeck EF, Lewis JA, Nalin DR et al. Safety profile and immunogenicity of an inactivated vacine derived from an attenuated strain of hepatitis A. Vaccine 1992; 10: 668-672.
9. Wiedermann G, Ambrosch F, Kollaritsch H et al. Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine 1990; 8: 581-584.
10. Delem AD, Safary A, Denamur F, Hauser P, Hondt d'E. Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis A. Vaccine 1993; 11: 479-484.
11. Binn LN, Macarthy PO, Marchwicki RH et al. Laboratory tests and reference reagents employed in studies of inactivated hepatitis A vaccine. Vaccine 1992; 10: S102-S105.
12. Heinricy U, Stierhof YD, Pfisterer M, Flehmig B. Properties of a hepatitis A virus candidate vaccine strain. J Gen Virol 1987; 68: 2487-2493.
13. Peetermans J. Production, quality control and characterization of an inactivated Hepatitis A vaccine. Vaccine 1992; 10: S99-S101.
14. Goilav C, Zuckerman JN, Lafrenz M et al. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J Med Virol 1995; 46: 287-292.
15. Miller WJ, Clark W, Hurni WM, Kuter B, Schofield T, Nalin DR. Sensitive assays for hepatitis A antibodies. J Med Virol 1993; 41: 201-204.
16. Werzberger A, Mensch BM Kuter B et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327: 453-457.
17. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271: 1328-1334.